sub News Events

Hero

Press Releases

Press Releases

Royalty Pharma Announces $1.14 Billion Acquisition of Royalty Rights in Cancer Drug Xtandi from the University of California, Los Angeles (UCLA)

Proceeds will fund research and scholarships; will also be shared with inventors. Los Angeles, CA (US) and New York, NY (US) – March 4, 2016  — UCLA and Royalty Pharma announced today that UCLA has sold its royalty interest connected with a leading prostate cancer medication, Xtandi, whose

Royalty Pharma Announces $3.3 Billion Royalty Transaction with Cystic Fibrosis Foundation Therapeutics

Largest pharmaceutical royalty purchase ever completed. Funds will be used to expand cystic fibrosis research, care and patient programs. New York, NY (US) – November 19, 2014  — Royalty Pharma announced today its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned

Avillion Announces Royalty Pharma Investment

Jim Reddoch, PhD, Royalty Pharma Executive Vice President for Research and Investments Joins Avillion Board. London (UK) and New York, NY (US) – May 6, 2014  — Avillion LLP, a company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development

Forest Laboratories and Royalty Pharma Announce Acquisition of Furiex Pharmaceuticals

Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI). Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest – Acquisition Adds Global

Royalty Pharma Announces Additional $510 Million Acquisition of Interest in Tecfidera and Fumaderm

New York, NY (US) – January 6, 2014  — Royalty Pharma announced today that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510 million in cash. The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec’s

FDA approves Imbruvica (ibrutinib) for mantle cell lymphoma (MCL)

Second drug with breakthrough therapy designation to receive FDA approval. Washington, DC (US) – November 13, 2013  — The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

Royalty Pharma Acquires Ibrutinib Royalty Rights for $485 Million In Cash

Retains royalty rights to odanacatib and other Celera drug assets. Madison, NJ (US) and New York, NY (US) – July 18, 2013  — Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today that it has completed the sale of its rights to

Royalty Pharma Announces Withdrawal of Judicial Review and Lapse of Offer

New York, NY (US) – June 18, 2013  — Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel’s decision requiring it to lapse its offer for Elan Corporation, plc (NYSE: ELN) if, among other things, Elan shareholders approved the Share

Royalty Pharma Raises $600 Million of Debt

New York, NY (US) – May 24, 2012  — Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully issued $600 million of incremental Term Loan B debt through RPI Finance Trust (“RPIFT”), bringing total

Royalty Pharma Announces $761 Million Acquisition of Interest in BG-12 and Fumaderm

Purchase of Interest in Fumapharm Earn-Out Represents Interest in BG-12 and Fumaderm. New York, NY (US) – May 2, 2012  — Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash.
Displaying 61 - 70 of 77